"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 7 | 1 | 8 |
| 2007 | 3 | 5 | 8 |
| 2008 | 10 | 2 | 12 |
| 2009 | 3 | 2 | 5 |
| 2010 | 4 | 2 | 6 |
| 2011 | 3 | 3 | 6 |
| 2012 | 3 | 2 | 5 |
| 2013 | 9 | 4 | 13 |
| 2014 | 5 | 4 | 9 |
| 2015 | 6 | 3 | 9 |
| 2016 | 0 | 2 | 2 |
| 2017 | 4 | 4 | 8 |
| 2018 | 1 | 7 | 8 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 7 | 8 |
| 2021 | 4 | 6 | 10 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 3 | 7 |
| 2025 | 3 | 4 | 7 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025 Sep 15; 385:119366.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
An audit of the HIV drug resistance testing program in Malawi. Malawi Med J. 2025 Mar; 37(1):16-22.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.
-
Birth outcomes following bictegravir exposure during pregnancy. AIDS. 2025 Mar 15; 39(4):381-386.